Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 18, 2024
Daily News
March 18, 2024
- FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
- Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
- Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
March 18, 2024
- Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
March 18, 2024
- Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
March 18, 2024
- BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
- Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
- Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
- Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…